1020315-31-4 | 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$82.00	$57.00
10mg	≥98%	in stock	$156.00	$109.00
25mg	95%	in stock	$172.00	$120.00
100mg	95%	in stock	$458.00	$320.00
1g	95%	in stock	$1,758.00	$1,231.00

Description

• Catalog Number: AA08102
• Chemical Name: 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-
• CAS Number: 1020315-31-4
• Molecular Formula: C23H20F3N5O2
• Molecular Weight: 455.4324
• MDL Number: MFCD18782721
• SMILES: O=C(N1CCC(=Cc2cccc(c2)Oc2ccc(cn2)C(F)(F)F)CC1)Nc1cccnn1

Computed Properties

• Complexity: 680
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 3.3

Literature

• Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.

  Science (New York, N.Y.) 20170609

• Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20140214

• Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.

  The Proceedings of the Nutrition Society 20140201

• An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee.

  Pain 20120901

• Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.

  British journal of clinical pharmacology 20120501

• Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.

  Pharmacological research 20120501

• Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain.

  The Journal of pharmacology and experimental therapeutics 20110701

• Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

  ACS medicinal chemistry letters 20110210

• Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.

  International review of psychiatry (Abingdon, England) 20090401